The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
n pre-clinical studies and early-stage clinical trials, PDE4 inhibitors such as rolipram have
been shown to enhance memory. They also improve depressive-like behaviors induced by chronic
unpredictable mild stress, lipopolysaccharide, or ethanol abstinence . Consequently, it is
reasonable to believe that PDE4 is a potential target for treatment of the comorbidity of
depression and AD.The aim of the current study is to evaluate the potential adjunct
antidepressant effect of the Phosphodiesterase-4 Inhibitor Roflumilast in adult patients with
MDD.